Molecular genotyping means finding genetic changes in tumor cells that help doctors choose the right cancer treatment. In the United States, lung cancer is one of the main causes of cancer deaths. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. It often needs detailed molecular testing to find the best treatments. Usually, this testing uses tissue genotyping. This means doctors take a sample from the tumor and analyze it using techniques like next-generation sequencing (NGS). This method is the standard, but it has some problems. Sometimes there is not enough tissue, the procedure is invasive, and it can take a long time to get results.
Liquid biopsies are blood tests that can be used alongside or instead of tissue genotyping. These tests look for pieces of tumor DNA or RNA that float in the blood. In US clinics, liquid biopsies can find important genetic mutations that help decide treatment plans. They usually work faster and can be done more than once. This lets doctors watch how the tumor changes over time.
Studies led by cancer experts like Dr. Luis E. Raez show that liquid biopsies work just as well as tissue genotyping in many cases. According to the International Society of Liquid Biopsy, using liquid biopsy can help start treatments sooner for NSCLC patients. This is useful when it is hard to get a tissue biopsy or when the tissue sample is too small or takes a long time to analyze.
Some cancer centers in the US now use a “plasma-first” method. This means they do a liquid biopsy before a tissue biopsy in patients suspected of having NSCLC. Testing the blood first can speed up treatment and find more genetic changes that can be treated.
Using the plasma-first method may help more lung cancer patients get the right therapies, especially in big hospitals and community clinics. But, to make this work well, hospitals need to plan carefully on testing steps, adjust workflows, and manage costs.
Using artificial intelligence (AI) and automated workflows can help healthcare providers in the US manage challenges with liquid biopsy tests.
Molecular testing creates large amounts of data. AI can help quickly analyze this data, find important mutations, suggest treatments, and identify clinical trials. For instance, AI tools like Tempus One help doctors search patient records and make decisions faster.
Automation can help track samples, schedule tests, report data, and manage billing. This reduces mistakes and saves time, which is important when testing many patients with different methods.
AI tools provide up-to-date clinical advice by combining molecular results with treatment guidelines and trial options. This helps doctors create treatment plans that fit each patient’s genetic profile.
AI speeds up the interpretation of test results and communication among pathology, oncology, and administration teams. This shortens the waiting time to begin treatment, especially for aggressive cancers like NSCLC.
With AI and automation, large health networks and academic centers can handle more molecular tests without reducing quality. This allows community clinics to access advanced testing too.
About 65% of US academic medical centers now use advanced AI tools for precision medicine. These centers, along with community hospitals and cancer groups, benefit from adding liquid biopsies and AI to improve patient care and workflow.
Liquid biopsies are useful not only for NSCLC but also for other cancers like breast, colorectal, and blood cancers. As the technology gets better and cheaper, more facilities are expected to use these tests.
Liquid biopsy tests will likely become a regular part of molecular cancer testing in the US. They help by adding more information to tissue genotyping. Together with AI tools and automation, they support smooth and patient-focused cancer care.
Less invasive testing combined with advanced data analysis can improve patient outcomes, shorten treatment delays, and make precision medicine more available in many healthcare settings across the country. Those who plan well for these technologies can help their organizations adjust to changes in cancer care.
By using liquid biopsy tests alongside tissue genotyping and AI tools, healthcare providers in the US can give timely, accurate, and customized cancer profiles. This can improve patient care and make operations more efficient.
AI accelerates the discovery of novel targets, predicts treatment effectiveness, identifies life-saving clinical trials, and diagnoses multiple diseases earlier, enhancing personalized patient care through advanced data analysis and algorithmic insights.
Tempus provides an AI-enabled assistant that helps physicians make more informed treatment decisions by analyzing multimodal real-world data and identifying personalized therapy options.
Tempus supports pharmaceutical and biotech companies with AI-driven drug development, leveraging extensive molecular profiling, clinical data integration, and algorithmic models to optimize therapeutic strategies.
The xT Platform combines molecular profiling with clinical data to identify targeted therapies and clinical trials, outperforming tumor-only DNA panel tests by using paired tumor/normal plus transcriptome sequencing.
It uses neural-network-based, high-throughput drug assays with light-microscopy to predict patient-specific drug response heterogeneity across various solid cancers, improving treatment personalization.
Liquid biopsy assays complement tissue genotyping by detecting actionable variants that might be missed otherwise, providing a more comprehensive molecular and clinical profiling for patients.
~65% of US Academic Medical Centers and over 50% of US oncologists are connected to Tempus, enabling wide adoption of AI-powered sequencing, clinical trial matching, and research partnerships.
Tempus One is an AI-enabled clinical assistant integrated into the Electronic Health Record (EHR) system, allowing custom query agents to maximize workflow efficiency and streamline access to patient data.
xM is a liquid biopsy assay designed to monitor molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors, offering real-time treatment response assessment.
Fuses combines Tempus’ proprietary datasets and machine learning to build the largest diagnostic platform, generating AI-driven insights and providing physicians a comprehensive suite of algorithmic tests for precision medicine.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
